STAA · Staar Surgical Co - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $239.44M | $313.90M | $322.42M | $284.39M | $230.47M | $163.46M |
| Cost of Revenue | $57.02M | $74.32M | $69.76M | $61.01M | $51.84M | $45.10M |
| Gross Profit | $182.42M | $239.58M | $252.65M | $223.38M | $178.64M | $118.36M |
| R&D | $40.05M | $53.97M | $44.40M | $35.98M | $33.86M | $31.92M |
| SG&A | $274.13M | $252.19M | $224.55M | $179.58M | $145.30M | $111.59M |
| Total Operating Expenses | - | - | - | - | - | - |
| D&A | $8.32M | $6.89M | $5.11M | $4.48M | $3.61M | $3.06M |
| Operating Income | ($91.71M) | ($12.61M) | $28.10M | $43.80M | $33.34M | $6.77M |
| Interest Expense | - | - | - | - | - | - |
| Income Tax | ($1.81M) | $11.16M | $12.35M | $6.80M | $6.80M | $2.35M |
| Net Income | ($80.45M) | ($20.21M) | $21.35M | $38.76M | $24.50M | $5.91M |
| EPS - Basic | ($1.62) | ($0.41) | $0.44 | $0.81 | $0.52 | $0.13 |
| EPS - Diluted | ($1.62) | ($0.41) | $0.43 | $0.78 | $0.50 | $0.12 |
Balance Sheet
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $153.15M | $144.16M | $183.04M | $86.48M | $199.71M | $152.45M |
| Accounts Receivable | $50.06M | $77.90M | $94.70M | $62.45M | $43.53M | $35.23M |
| Inventory | $58.42M | $44.58M | $38.64M | $25.84M | $18.43M | $19.57M |
| Accounts Payable | $11.57M | $16.70M | $13.56M | $11.58M | $8.70M | $7.87M |
| Current Assets | $311.55M | $367.94M | $365.27M | $311.72M | $271.41M | $216.42M |
| Total Assets | $451.68M | $509.52M | $488.69M | $414.90M | $345.78M | $257.42M |
| Current Liabilities | $68.50M | $70.31M | $65.04M | $51.72M | $48.80M | $41.24M |
| Long-term Debt | - | - | - | - | - | - |
| Total Liabilities | $107.49M | $112.19M | $102.74M | $82.71M | $87.22M | $60.19M |
| Stockholders' Equity | $344.18M | $397.33M | $385.95M | $332.19M | $258.56M | $197.22M |
| Retained Earnings | ($148.02M) | ($67.58M) | ($47.37M) | ($72.64M) | ($111.39M) | ($135.89M) |
Cash Flow
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | ($34.23M) | $15.72M | $14.59M | $35.72M | $43.96M | $20.95M |
| Investing Cash Flow | $46.34M | ($59.22M) | $74.35M | ($156.38M) | ($13.64M) | ($8.40M) |
| Financing Cash Flow | ($4.55M) | $5.72M | $7.42M | $8.30M | $17.79M | $19.57M |
| CapEx | $5.82M | $23.39M | $18.19M | $18.11M | $13.64M | $8.40M |
| Free Cash Flow | ($40.05M) | ($7.67M) | ($3.59M) | $17.61M | $30.32M | $12.55M |
Ratios
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | 76.2% | 76.3% | 78.4% | 78.5% | 77.5% | 72.4% |
| Operating margin | -38.3% | -4.0% | 8.7% | 15.4% | 14.5% | 4.1% |
| EBITDA margin | -34.8% | -1.8% | 10.3% | 17.0% | 16.0% | 6.0% |
| Net margin | -33.6% | -6.4% | 6.6% | 13.6% | 10.6% | 3.6% |
| Free cash flow margin | -16.7% | -2.4% | -1.1% | 6.2% | 13.2% | 7.7% |
| FCF / Net income | 0.50 | 0.38 | -0.17 | 0.45 | 1.24 | 2.12 |
| R&D / Revenue | 16.7% | 17.2% | 13.8% | 12.7% | 14.7% | 19.5% |
| SG&A / Revenue | 114.5% | 80.3% | 69.6% | 63.1% | 63.0% | 68.3% |
| Effective tax rate | - | - | 36.6% | 14.9% | 21.7% | 28.5% |
| Return on assets | -17.8% | -4.0% | 4.4% | 9.3% | 7.1% | 2.3% |
| Return on equity | -23.4% | -5.1% | 5.5% | 11.7% | 9.5% | 3.0% |
| Return on invested capital | - | - | - | - | - | - |
| Liquidity | ||||||
| Current ratio | 4.55 | 5.23 | 5.62 | 6.03 | 5.56 | 5.25 |
| Quick ratio | 3.69 | 4.60 | 5.02 | 5.53 | 5.18 | 4.77 |
| Cash ratio | 2.24 | 2.05 | 2.81 | 1.67 | 4.09 | 3.70 |
| Leverage | ||||||
| Debt / Equity | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - |
| Interest coverage | - | - | - | - | - | - |
| Equity multiplier | 1.31 | 1.28 | 1.27 | 1.25 | 1.34 | 1.31 |
| Liabilities / Assets | 0.24 | 0.22 | 0.21 | 0.20 | 0.25 | 0.23 |
| Efficiency | ||||||
| Asset turnover | 0.53 | 0.62 | 0.66 | 0.69 | 0.67 | 0.64 |
| Inventory turnover | 0.98 | 1.67 | 1.81 | 2.36 | 2.81 | 2.30 |
| Days sales outstanding | 76d | 91d | 107d | 80d | 69d | 79d |
| Days inventory outstanding | 374d | 219d | 202d | 155d | 130d | 158d |
| Days payable outstanding | 74d | 82d | 71d | 69d | 61d | 64d |
| Cash conversion cycle | 376d | 227d | 238d | 165d | 137d | 173d |
| Valuation | ||||||
| P / E | - | - | 72.6x | 62.2x | 182.6x | 660.2x |
| P / B | 3.4x | 3.0x | 4.0x | 7.2x | 17.5x | 19.3x |
| P / S | 4.9x | 3.8x | 4.8x | 8.4x | 19.6x | 23.2x |
| EV / EBITDA | - | - | 40.9x | 47.9x | 116.8x | 371.0x |
| Growth | ||||||
| Revenue growth (YoY) | -23.7% | -2.6% | 13.4% | 23.4% | 41.0% | 8.8% |
| Revenue CAGR (3y) | -5.6% | 10.8% | 25.4% | 23.7% | 40.9% | 21.7% |
| Revenue CAGR (5y) | 7.9% | 15.9% | 31.4% | 25.7% | 22.8% | 16.2% |
| Gross profit growth (YoY) | -23.9% | -5.2% | 13.1% | 25.0% | 50.9% | 5.7% |
| Operating income growth (YoY) | -627.2% | - | -35.9% | 31.4% | 392.5% | -42.9% |
| Net income growth (YoY) | -298.1% | - | -44.9% | 58.2% | 314.4% | -57.9% |
| EPS growth (YoY) | -295.1% | - | -44.9% | 56.0% | 316.7% | -60.0% |
| EPS CAGR (3y) | - | - | 53.0% | 37.5% | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - |
| FCF growth (YoY) | -422.2% | -113.4% | - | -41.9% | 141.6% | -20.1% |
| FCF CAGR (5y) | - | - | - | - | - | - |
| Book value growth (YoY) | -13.4% | 2.9% | 16.2% | 28.5% | 31.1% | 23.4% |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2026-01-02.
Geographic
$182.64M totalOther Countries$93.84M · 51.4%
JP$45.27M · 24.8%
CN$43.53M · 23.8%
Stability scores
Altman Z′
FY 2025 · bankruptcy risk
1.35
Grey zone
Private-firm variant - uses book equity instead of market cap. > 2.90 safe · 1.23-2.90 grey · < 1.23 distress.
Piotroski F-score
FY 2025 · 9-point quality
2/9
Weak
- ✗Net income positive
- ✗Operating cash flow positive
- ✗ROA improved YoY
- ✓Cash flow > net income
- -Long-term debt decreased
- ✗Current ratio improved
- ✓No share dilution
- ✗Gross margin improved
- ✗Asset turnover improved
Peer comparison
Same SIC group: Ophthalmic Goods
Comparing STAAR SURGICAL CO against the 5 most active filers in the same SIC group.